TrialNature communications2024

A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.

Terese C Hammond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.